Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 7/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | MC4R | P32245 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709410 | 0.93 | NPC1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL17896908 | 0.93 | GRM2 (0.57) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL6709496 | 0.93 | NPSR1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL6709521 | 0.92 | KDM4E (0.48) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL6714914 | 0.91 | GRM2 (0.46) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL6712622 | 0.90 | HTT (0.52) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL6709458 | 0.88 | CSF1R (0.51) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL6708251 | 0.88 | HPGD (0.45) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL6712544 | 0.88 | NPSR1 (0.51) | ALDH1A1KDM4EHPGDHSD17B10GRM2 | |
| SCHEMBL6710753 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDHSD17B10GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024209-A1 | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-02-05 | — | — | US | disclosed |
| US-6653307-B2 | Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | disclosed |
| CN-1432001-A | 1-aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | UPJOHN CO (US) | 2003-07-23 | — | — | CN | disclosed |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024209-A1 | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, IRF3 | ALDH1A1 668/4885KDM4E 314/4885HPGD 3230/4885 |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, ZC3HAV1L | ALDH1A1 463/4885KDM4E 178/4885HPGD 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.